Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

Maria E. Suarez-Almazor, Xerxes Pundole, Noha Abdel-Wahab, Douglas B. Johnson, Dipti Gupta, Ilya Glezerman, Tim Cooksley, Ronald Anderson, Ada Blidner, Jennifer Choi, Michael Dougan, Pamela Ginex, Monica Girotra, Vickie R. Shannon, Bernardo L. Rapoport*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.

Original languageEnglish (US)
Pages (from-to)6159-6173
Number of pages15
JournalSupportive Care in Cancer
Volume28
Issue number12
DOIs
StatePublished - Dec 2020

Keywords

  • Arthralgia
  • Arthritis
  • Cardiomyopathy
  • Corticosteroids
  • Immunomodulation agents
  • Myocarditis
  • Myositis
  • Other immunosuppressive agents
  • Polymyalgia

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this